Recombinant protein technology provider Healthgen netted over $87m while shared living space provider Hmlet is buying corporate-backed peer Habyt and Uniswap Labs is launching an investment vehicle.

Funding

Pharmaceutical company Betta Pharmaceuticals has co-led a RMB556m ($87.3m) funding round for China-based recombinant protein technology developer Healthgen Biotechnology, DealStreetAsia reported yesterday, citing a company announcement. The investor that co-led the round was not disclosed but it is expected to be the last for Healthgen before it launches an initial public offering.

Tive, a US-based provider of supply chain visibility software, completed a $54m series B round yesterday led by Axa Venture Partners, the venture capital firm sponsored by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn